<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="22">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 14, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04010799</url>
  </required_header>
  <id_info>
    <org_study_id>CLI-06333AA1-16</org_study_id>
    <secondary_id>2018-002508-15</secondary_id>
    <nct_id>NCT04010799</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis</brief_title>
  <official_title>A Phase Ib, Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF 6333 After Single and Repeated Ascending Doses in Patients Affected by Cystic Fibrosis and Non Cystic Fibrosis Bronchiectasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CHF 6333 is a medicinal product on development for the treatment of cystic fibrosis and&#xD;
      non-CF bronchiectasis and undergoing clinical testing. It has not yet been approved by the&#xD;
      authorities for the treatment of these diseases.&#xD;
&#xD;
      CHF6333 is an inhaled anti-inflammatory which mechanism of action is based on the inhibition&#xD;
      of Human Neutrofil Elastase.&#xD;
&#xD;
      The safety and tolerability of single and repeated ascending doses of inhaled CHF 6333 was&#xD;
      previously investigated in healthy subjects: information was gathered on the uptake,&#xD;
      distribution and excretion of the medicinal product being tested (pharmacokinetics). In this&#xD;
      current clinical trial CHF 6333 will be tested in patients(CF and NCFB) for the first time.&#xD;
&#xD;
      Three dose level will be tested during the first part of the study, as single administration.&#xD;
      One repeated dose will be administered in the second part of the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 27, 2019</start_date>
  <completion_date type="Actual">March 8, 2021</completion_date>
  <primary_completion_date type="Actual">March 8, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Part I:&#xD;
Randomised, double-blind, placebo-controlled, single-dose escalation, cross-over design in one cohort of CF patients and in one cohort of NCFB patients.&#xD;
Part II:&#xD;
Randomised, double-blind, placebo-controlled, repeated-dose, parallel-group design in one cohort of CF patients and in one cohort of NCFB patients.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event</measure>
    <time_frame>Part I: Baseline through end of treatment (up to a maximum of 30 days after last study drug intake) ; Part II Baseline through end of treatment (up to a maximum of 30 days after last study drug intake)</time_frame>
    <description>Occurrence and severity of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Vital signs</measure>
    <time_frame>Part I: Day 1 pre-dose up to 6 hours post dose. Part II: Day 1 and Day 7 pre dose up to 6 hours post dose</time_frame>
    <description>Change in Systolic and Diastolic blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Part I: Day 1 pre dose up to 8 hours post dose. Part II: Day 1 and Day 7 pre dose up to 12 hours post dose</time_frame>
    <description>Change in Heart Rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PR interval</measure>
    <time_frame>Part I: Day 1 pre dose up to 8 hours post dose. Part II: Day 1 and Day 7 pre dose up to 12 hours post dose</time_frame>
    <description>Change in PR interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QRS interval</measure>
    <time_frame>Part I: Day 1 pre dose up to 8 hours post dose. Part II: Day 1 and Day 7 pre dose up to 12 hours post dose</time_frame>
    <description>Change in QRS interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QTCf interval</measure>
    <time_frame>Part I: Day 1 pre dose up to 8 hours post dose. Part II: Day 1 and Day 7 pre dose up to 12 hours post dose</time_frame>
    <description>Change in QTCf interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FEV1</measure>
    <time_frame>Part I: Day 1 pre dose up to 6 hours post dose. Part II: Day 1 and Day 7 pre dose up to 6 hours post dose. Day 2 -6: pre dose up to 2 hours post dose</time_frame>
    <description>Change in FEV1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>Part I: Day 1. Part II Day 1-7</time_frame>
    <description>Area under the plasma concentration curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Part I: Day 1. Part II Day 1-7</time_frame>
    <description>Peak plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T max</measure>
    <time_frame>Part I: Day 1. Part II Day 1-7</time_frame>
    <description>Time to reach the maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C24h</measure>
    <time_frame>Part II: Day 5 Day 6</time_frame>
    <description>Trough drug concentration 24 h post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rac</measure>
    <time_frame>Part II: Day 7</time_frame>
    <description>Accumulation ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NE activity</measure>
    <time_frame>Part I: Day -1 Day 1. Part II: Day -1 - 7</time_frame>
    <description>Change in neutrophil elastase activity in sputum</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Non-Cystic Fibrosis Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>CHF6333</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF6333 Active (part I - SAD). Once daily inhaled single dose of CHF6333 at each period (three dose level).&#xD;
CHF6333 Active (part II -MD). Once daily inhaled multiple dose of CHF6333 for 7 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF6333 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part I (SAD): Single dose of placebo matching CHF6333 at each period&#xD;
Part II (MD): Once daily multiple doses of placebo matching CHF6333 for 7 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 6333</intervention_name>
    <description>CHF 6333 - Part I - SAD CHF 6333 - Part II - MD</description>
    <arm_group_label>CHF6333</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo - Part I - SAD Placebo Part II - MAD</description>
    <arm_group_label>CHF6333 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
        CF patients:&#xD;
&#xD;
          -  Patient's written informed consent obtained prior to any study-related procedure;&#xD;
&#xD;
          -  Male or female patient ≥ 18 years old with a confirmed historical diagnosis of cystic&#xD;
             fibrosis;&#xD;
&#xD;
          -  Ability to provide a spontaneous sputum sample at screening;&#xD;
&#xD;
          -  Non- or ex-smokers who smoked &lt; 10 pack years and stopped smoking &gt; 1 year before&#xD;
             screening visit;&#xD;
&#xD;
          -  Patient in stable clinical condition and free from exacerbation for at least 4 weeks&#xD;
             prior to screening and/or prior to randomisation;&#xD;
&#xD;
          -  Patient on stable concomitant treatment regimen within 4 weeks prior to screening&#xD;
             and/or prior to randomisation;&#xD;
&#xD;
          -  Patient with pre-bronchodilator FEV1 ≥ 50% of predicted normal at screening and/or&#xD;
             prior to randomisation;&#xD;
&#xD;
          -  Vital signs within normal limits at screening and prior to randomisation;&#xD;
&#xD;
        NCFB patients:&#xD;
&#xD;
          -  Patient's written informed consent obtained prior to any study-related procedure;&#xD;
&#xD;
          -  Male or female patient ≥ 18 years old with a diagnosis of Bronchiectasis confirmed by&#xD;
             a historical Chest CT;&#xD;
&#xD;
          -  Presence of clinically significant symptoms related to Bronchiectasis, such as daily&#xD;
             cough that occurs over months or years, daily production of large amount of sputum,&#xD;
             shortness of breath, wheezing chest pain;&#xD;
&#xD;
          -  Ability to provide a spontaneous sputum sample at screening;&#xD;
&#xD;
          -  Non- or ex-smokers who smoked &lt; 10 pack years and stopped smoking &gt; 1 year before&#xD;
             screening visit;&#xD;
&#xD;
          -  Patients in stable clinical condition and free from exacerbation since at least 4&#xD;
             weeks before screening and/or prior to randomisation;&#xD;
&#xD;
          -  Patients on stable concomitant treatment regimen within 4 weeks prior to screening&#xD;
             and/or prior to randomisation&#xD;
&#xD;
          -  Patient with pre- bronchodilator FEV1 ≥ 50% of predicted normal at screening and/or&#xD;
             prior randomization visit;&#xD;
&#xD;
          -  Vital signs within normal limits at screening and prior to randomisation&#xD;
&#xD;
        EXCLUSION CRITERIA CF Patients&#xD;
&#xD;
          -  Patient with BMI ≤ 17&#xD;
&#xD;
          -  History of a clinically meaningful unstable or uncontrolled chronic comorbidity in the&#xD;
             opinion of the Investigator;&#xD;
&#xD;
          -  Unstable pulmonary status or symptomatic respiratory tract infection and related&#xD;
             changes in therapy for pulmonary disease as per Investigator's judgment within 4 weeks&#xD;
             before screening or prior to randomisation;&#xD;
&#xD;
          -  Abnormal and clinically significant 12-lead ECG at screening or prior to&#xD;
             randomisation;&#xD;
&#xD;
          -  History of asthma based on objective evidence;&#xD;
&#xD;
          -  History of malignancy, solid organ/haematological transplantation;&#xD;
&#xD;
          -  Patient with evidence of active Nontuberculous Mycobacteria (NTM) and Tuberculous&#xD;
             Mycobacteria (TM) infection or related bronchiectasis in the past 12 months;&#xD;
&#xD;
          -  Patient with a positive test for active Allergic Bronchopulmonary Aspergillosis (ABPA)&#xD;
             infection confirmed at screening or patient withABPA related bronchiectasis.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Patient on non-steroidal anti-inflammatory drugs (NSAIDs) within 4 weeks prior to&#xD;
             screening or prior to randomization visit.&#xD;
&#xD;
          -  Patient on cystic fibrosis transmembrane conductance regulator (CFTR) modulators and&#xD;
             correctors if not on stable treatment regimen for at least 3 months prior to screening&#xD;
             or prior to randomization.&#xD;
&#xD;
          -  Positive HIV1 or HIV2 serology at screening; Positive results from the Hepatitis&#xD;
             serology which indicates acute or chronic Hepatitis B or Hepatitis C at screening&#xD;
             (i.e. positive HB surface antigen (HBsAg), HB core antibody (anti-HBc), HC antibody);&#xD;
&#xD;
        NCFB Patients&#xD;
&#xD;
          -  Patient with BMI ≤ 17&#xD;
&#xD;
          -  History of a clinically meaningful unstable or uncontrolled chronic comorbidity in the&#xD;
             opinion of the Investigator;&#xD;
&#xD;
          -  Unstable pulmonary status or symptomatic respiratory tract infection and related&#xD;
             changes in therapy for pulmonary disease as per Investigator's judgment within 4 weeks&#xD;
             before screening or prior to randomisation.&#xD;
&#xD;
          -  Abnormal and clinically significant 12-lead ECG at screening or prior to randomisation&#xD;
             that results in active medical problem which may impact the safety of the patients as&#xD;
             per Investigator's judgment.&#xD;
&#xD;
          -  History of malignancy, solid organ/haematological transplantation;&#xD;
&#xD;
          -  Known diagnosis of cystic fibrosis. A negative sweat test is required at screening&#xD;
             (sweat chloride should be &lt; 40 mmol/L);&#xD;
&#xD;
          -  History of asthma based on objective evidence of the condition;&#xD;
&#xD;
          -  Patient with primary diagnosis of COPD in the opinion of theInvestigator;&#xD;
&#xD;
          -  Patient with rheumatoid factor positivity;&#xD;
&#xD;
          -  Patient with evidence of active Nontuberculous Mycobacteria (NTM) and Tuberculous&#xD;
             Mycobacteria (TM) infection or related bronchiectasis in the past 12 months;&#xD;
&#xD;
          -  Patient with a positive test for active Allergic Bronchopulmonary Aspergillosis (ABPA)&#xD;
             infection confirmed at screening or patient with ABPA related bronchiectasis;&#xD;
&#xD;
          -  Patient with Connective Tissue Disease (CTD) related bronchiectasis;&#xD;
&#xD;
          -  Diagnosis of common variable immunodeficiency (CVID);&#xD;
&#xD;
          -  Patient on any antibiotics (except for stable macrolides treatment),oral, inhaled and&#xD;
             IV, within 4 weeks prior to screening or prior to randomisation;&#xD;
&#xD;
          -  Patient on oral corticosteroids within 4 weeks prior to screening visit or prior to&#xD;
             randomization.&#xD;
&#xD;
          -  Patient on non-steroidal anti-inflammatory drugs (NSAIDs) within 4 weeks prior to&#xD;
             screening or randomization visit.&#xD;
&#xD;
          -  Patient on Carbocysteine and Mannitol treatment within 4 weeks before the screening or&#xD;
             randomization visit.&#xD;
&#xD;
          -  Patient with traction bronchiectasis;&#xD;
&#xD;
          -  Patient with any condition that prevent them to use inhaledantibiotics (including&#xD;
             patients who previously experienced adverse reaction to inhaled antibiotics;&#xD;
&#xD;
          -  Patient treated with monoclonal antibodies (mAb);&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Positive HIV1 or HIV2 serology at screening; Positive results from the Hepatitis&#xD;
             serology which indicates acute or chronic Hepatitis B or Hepatitis C at screening&#xD;
             (i.e. positive HB surface antigen (HBsAg), HBcore antibody (anti-HBc), HC antibody).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IKF Institut für klinische Forschung Pneumologie</name>
      <address>
        <city>Frankfurt/Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2019</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Bronchiectasis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

